You (and your doctor friend) are correct: the absence of any SAEs (adverse events) at this stage of the game is a huge plus!
Moreover the lack of liver biopsy, which seems to bother some of these Galectin trial critics, is in fact a non-issue. Liver specialists (hepatologists) use biopsies with clearly decreasing frequency. The relatively new blood tests such as FibroSure (which measures a panel of reliable blood markers) can tell as much - indeed more - about the liver's condition, and in particular its function - than a biopsied tissue sample does. Add the new technology of elastography - the radiological assessment of the liver's "stiffness" - into the equation, and you have a diagnostic toolkit that surpasses any biopsy!!
Let the hecklers and critics have their day! There are many of us who know better - and we'll have the last laugh!
News 
Market Data 
Discover 
